Actinium Pharmaceuticals Announces Filing of Provisional Patent Application
Complete the form below to unlock access to ALL audio articles.
Actinium Pharmaceuticals, Inc. has announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B.
A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a subsequent patent with similar claims. Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals said, "This provisional patent application represents another valuable addition to our intellectual property portfolio. We remain committed to the strategic enhancement of our intellectual property portfolio in alignment with our development of targeted payload immunotherapeutics."
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, "2016 will be a transformational year for Actinium as we transition to a later stage company with the commencement of the Iomab-B Phase 3 pivotal trial and the Actimab-A Phase 2 clinical trial. The strengthening of our intellectual property portfolio is an integral aspect of Actinium's growth and today's provisional patent application demonstrates our commitment to this goal."
Actinium's broad intellectual property portfolio includes 39 issued and pending patents in the U.S. and internationally. This includes 7 issued patents in the United States, 2 pending patents in the United States and 30 issued or pending international patents. The Company's patent portfolio encompasses the use of alpha emitting isotopes attached to monoclonal antibodies, methods for manufacturing key components of its product candidates and methods for manufacturing finished product candidates for use in cancer treatment.